Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28245279 | 0.98 | CXCR4 (0.44) | POLBSMN1; SMN2CXCR4LOXHSD17B10 | |
| Hydrochloric Acid SCHEMBL1155904 | 0.98 | POLB (0.41) | POLBSMN1; SMN2CXCR4LOXHSD17B10 | |
| Hydrochloric Acid SCHEMBL309825 | 0.98 | POLB (0.41) | POLBSMN1; SMN2CXCR4LOXHSD17B10 | |
| SCHEMBL2007988 | 0.92 | CXCR4 (0.53) | POLBSMN1; SMN2CXCR4LOXMEN1 | |
| Hydrochloric Acid SCHEMBL2013998 | 0.91 | CXCR4 (0.52) | POLBSMN1; SMN2CXCR4LOXMEN1 | |
| SCHEMBL1023067 | 0.88 | CXCR4 (0.47) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5485399 | 0.88 | POLB (0.34) | POLBSMN1; SMN2CXCR4LOXHSD17B10 | |
| Hydrochloric Acid SCHEMBL15735731 | 0.86 | CXCR4 (0.46) | POLBSMN1; SMN2CXCR4SIGMAR1CHRM5 | |
| Hydrochloric Acid SCHEMBL1547051 | 0.86 | CXCR4 (0.46) | POLBSMN1; SMN2CXCR4SIGMAR1CHRM5 | |
| SCHEMBL7351993 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
| WO-2023225634-A2 | METHODS FOR THE ENHANCEMENT OF THERAPEUTIC EFFECT OF CAR-T CELLS | IMAGO BIOSCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097187-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-1758868-A1 | NOVEL CIS-IMIDAZOLINES | F. Hoffmann-La Roche AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| US-7132426-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| CN-1829718-A | Fused aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1644375-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005123691-A1 | NOVEL CIS-IMIDAZOLINES | F-HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282803-A1 | CIS-imidazolines | HALEY GREGORY J | 2005-12-22 | — | — | US | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005007658-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-0703905-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | POLB 2152/4885SMN1; SMN2 4669/4885CXCR4 3754/4885 |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | POLB 3408/4885SMN1; SMN2 3267/4885CXCR4 1786/4885 |
| US-20050282803-A1 | CIS-imidazolines | PPIP5K2, PIN1, CCNI | POLB 2679/4885SMN1; SMN2 2154/4885CXCR4 945/4885 |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | POLB 2152/4885SMN1; SMN2 4669/4885CXCR4 3754/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | POLB 3408/4885SMN1; SMN2 3267/4885CXCR4 1786/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | POLB 1529/4885SMN1; SMN2 1176/4885CXCR4 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.